SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-16-153723
Filing Date
2016-11-01
Accepted
2016-11-01 16:07:17
Documents
9
Period of Report
2016-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a16-20866_18k.htm 8-K 36686
2 EX-2.1 a16-20866_1ex2d1.htm EX-2.1 1200404
3 EX-99.1 a16-20866_1ex99d1.htm EX-99.1 28976
4 GRAPHIC g208661kg31i001.gif GRAPHIC 277720
5 GRAPHIC g208661kg31i002.gif GRAPHIC 422760
6 GRAPHIC g208661kg31i003.gif GRAPHIC 359939
7 GRAPHIC g208661kg31i004.gif GRAPHIC 328867
8 GRAPHIC g208661kg29i001.jpg GRAPHIC 808
9 GRAPHIC g208661mmi001.jpg GRAPHIC 4864
  Complete submission text file 0001104659-16-153723.txt   3188243
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 161964829
SIC: 2835 In Vitro & In Vivo Diagnostic Substances